Overview

A Study in Participants With Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is: - To compare the blood sugar control of LY2605541 with insulin glargine after 78 weeks of treatment. - To compare the rate of night-time low blood sugar episodes on LY2605541 with insulin glargine during 78 weeks of treatment. - To compare the number of participants on LY2605541 reaching blood sugar targets without low blood sugar episodes at night to those taking insulin glargine after 78 weeks of treatment. - To compare the rate of hypoglycemia episodes on LY2605541 with insulin glargine during 78 weeks of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Boehringer Ingelheim
Treatments:
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc